SCHEMBL6367494

SCHEMBL6367494

Fc1ccc(-c2noc(Cl)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HTT P42858 1/20 0.53
SIRT2 Q8IXJ6 1/20 0.51
CASP3 P42574 5/20 0.50
SENP8 Q96LD8 3/20 0.50
SENP7 Q9BQF6 3/20 0.50
SENP6 Q9GZR1 2/20 0.50
TP53 P04637 2/20 0.50
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ATM Q13315 1/20 0.47
NOTUM Q6P988 2/20 0.44
NR1H4 Q96RI1 1/20 0.44
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HDAC8 Q9BY41 1/20 0.43
GRM5 P41594 1/20 0.43
HDAC4 P56524 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19555861 0.83 NOTUM (0.61) NPC1RAB9ASMN1; SMN2HTTSIRT2
SCHEMBL17100937 0.79 NR1H4 (0.68) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL3770905 0.78 NR1H4 (0.65) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL2360966 0.78 L3MBTL1 (0.58) NPC1RAB9ASMN1; SMN2HTTSIRT2
SCHEMBL2360965 0.78 NPC1 (0.51) NPC1RAB9ASMN1; SMN2HTTSIRT2
SCHEMBL24061386 0.78 NOTUM (0.66) NPC1RAB9ASMN1; SMN2HTTSIRT2
SCHEMBL2107628 0.77 NPC1 (0.64) NPC1RAB9ASMN1; SMN2HTTSIRT2
SCHEMBL4552118 0.77 CASP3 (0.78) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL3059321 0.75 NR1H4 (0.78) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL16217987 0.75 HDAC6 (0.69) HDAC1HDAC6HDAC8HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113382767-B Urea compounds having substituents 第一三共株式会社 2024-12-24 CN disclosed
US-11981686-B2 Urea compound having substituent DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-05-14 US disclosed
US-20230058950-A1 UREA COMPOUND HAVING SUBSTITUENT DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-23 US disclosed
US-20230058950-A1 UREA COMPOUND HAVING SUBSTITUENT DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-23 US disclosed
EP-3915558-A1 SUBSTITUENT-INCLUDING UREA COMPOUND Daiichi Sankyo Company, Limited (JP) 2021-12-01 EP disclosed
EP-3915558-A1 SUBSTITUENT-INCLUDING UREA COMPOUND Daiichi Sankyo Company, Limited (JP) 2021-12-01 EP disclosed
CN-113382767-A Substituted urea compounds 第一三共株式会社 2021-09-10 CN disclosed
WO-2020153432-A1 AMINO ACID COMPOUND 第一三共株式会社 2020-07-30 WO disclosed
WO-2020153433-A1 SUBSTITUENT-INCLUDING UREA COMPOUND 第一三共株式会社 2020-07-30 WO disclosed
WO-2020153433-A1 SUBSTITUENT-INCLUDING UREA COMPOUND 第一三共株式会社 2020-07-30 WO disclosed
WO-2020153432-A1 AMINO ACID COMPOUND 第一三共株式会社 2020-07-30 WO disclosed
US-20050043545-A1 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors GLAXO GROUP LIMITED (GB) 2005-02-24 US disclosed
EP-1440070-A1 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-28 EP disclosed
WO-2003037894-A1 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS GLAXO GROUP LIMITED (GB) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981686-B2 Urea compound having substituent SIRT6, SIRT1, SIRT2 NPC1 1240/4885RAB9A 3232/4885SMN1; SMN2 2464/4885
US-20230058950-A1 UREA COMPOUND HAVING SUBSTITUENT SIRT6, SIRT1, SIRT2 NPC1 1240/4885RAB9A 3232/4885SMN1; SMN2 2464/4885
US-20050043545-A1 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors NR1H3, NR1H2, NR1I3 NPC1 197/4885RAB9A 1951/4885SMN1; SMN2 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.